$ILNS Recent News 10-Q: INTELLECT NEUROSCIENCES,
Post# of 94145
Posted On: 01/30/2014 2:29:19 PM
$ILNS Recent News
10-Q: INTELLECT NEUROSCIENCES, INC. 4:03 p.m. Nov. 19, 2013 - Edgar Online - (EDG = 10Q, 10K)
10-K: INTELLECT NEUROSCIENCES, INC. 4:31 p.m. Oct. 15, 2013 - Edgar Online - (EDG = 10Q, 10K)
10-Q: INTELLECT NEUROSCIENCES, INC. 2:41 p.m. May 20, 2013 - Edgar Online - (EDG = 10Q, 10K)
10-Q: INTELLECT NEUROSCIENCES, INC. 2:27 p.m. Feb. 12, 2013 - Edgar Online - (EDG = 10Q, 10K)
Revenues Fall at ViroPharma - Analyst Blog 12:30 p.m. Oct. 29, 2012 - Zacks.com
ViroPharma Beats; All Set to Shine - Analyst Blog 9:15 a.m. March 2, 2012 - Zacks.com
ViroPharma Going Strong - Analyst Blog 8:45 a.m. Oct. 31, 2011 - Zacks.com
Intellect Neurosciences, Inc. Announces Positive Top Line Data Showing Proof of Concept in a Preclinical Alzheimer's Model for Its TauC3 Monoclonal Antibody Indicating its Potential to be Disease Modifying 3:20 a.m. Jan. 16, 2014 - GlobeNewswire
Intellect Neurosciences Obtains Patent Allowance From the United States Patent and Trademark Office in Relation to Its TOC-1 Monoclonal Antibody Selective for Pre-Fibrillar Tau Aggregates 2:15 p.m. Nov. 14, 2013 - GlobeNewswire
Intellect Neurosciences Retains Chain Pharmaceuticals LLC 10:30 a.m. July 30, 2013 - GlobeNewswire
Intellect Neurosciences, Inc. Issues Letter to Shareholders 8:26 a.m. June 20, 2013 - GlobeNewswire
Intellect Neurosciences Engages Evli Corporate Finance to Explore Strategic Alternatives to Maximize Shareholder Value 10:31 a.m. June 18, 2013 - GlobeNewswire
Intellect Neurosciences Issues Letter to Shareholders 8:35 a.m. March 29, 2013 - GlobeNewswire
Intellect Neurosciences to Present at Bio-Europe Spring Conference in Barcelona 9:35 a.m. Feb. 28, 2013 - GlobeNewswire
Intellect Neurosciences Issues Letter to Shareholders 12:33 p.m. Feb. 13, 2013 - GlobeNewswire
Intellect Neurosciences Initiates in vivo Proof of Concept Studies in a Preclinical Alzheimer's Model for Its TauC3 Monoclonal Antibody 9:35 a.m. Feb. 7, 2013 - GlobeNewswire
Novel Alzheimer's Therapeutics Developer Says Investors Should Remain Undeterred Despite Disappointing Results From Major Phase 3 Trials 8:08 a.m. Jan. 30, 2013 - Marketwire
10-Q: INTELLECT NEUROSCIENCES, INC. 4:03 p.m. Nov. 19, 2013 - Edgar Online - (EDG = 10Q, 10K)
10-K: INTELLECT NEUROSCIENCES, INC. 4:31 p.m. Oct. 15, 2013 - Edgar Online - (EDG = 10Q, 10K)
10-Q: INTELLECT NEUROSCIENCES, INC. 2:41 p.m. May 20, 2013 - Edgar Online - (EDG = 10Q, 10K)
10-Q: INTELLECT NEUROSCIENCES, INC. 2:27 p.m. Feb. 12, 2013 - Edgar Online - (EDG = 10Q, 10K)
Revenues Fall at ViroPharma - Analyst Blog 12:30 p.m. Oct. 29, 2012 - Zacks.com
ViroPharma Beats; All Set to Shine - Analyst Blog 9:15 a.m. March 2, 2012 - Zacks.com
ViroPharma Going Strong - Analyst Blog 8:45 a.m. Oct. 31, 2011 - Zacks.com
Intellect Neurosciences, Inc. Announces Positive Top Line Data Showing Proof of Concept in a Preclinical Alzheimer's Model for Its TauC3 Monoclonal Antibody Indicating its Potential to be Disease Modifying 3:20 a.m. Jan. 16, 2014 - GlobeNewswire
Intellect Neurosciences Obtains Patent Allowance From the United States Patent and Trademark Office in Relation to Its TOC-1 Monoclonal Antibody Selective for Pre-Fibrillar Tau Aggregates 2:15 p.m. Nov. 14, 2013 - GlobeNewswire
Intellect Neurosciences Retains Chain Pharmaceuticals LLC 10:30 a.m. July 30, 2013 - GlobeNewswire
Intellect Neurosciences, Inc. Issues Letter to Shareholders 8:26 a.m. June 20, 2013 - GlobeNewswire
Intellect Neurosciences Engages Evli Corporate Finance to Explore Strategic Alternatives to Maximize Shareholder Value 10:31 a.m. June 18, 2013 - GlobeNewswire
Intellect Neurosciences Issues Letter to Shareholders 8:35 a.m. March 29, 2013 - GlobeNewswire
Intellect Neurosciences to Present at Bio-Europe Spring Conference in Barcelona 9:35 a.m. Feb. 28, 2013 - GlobeNewswire
Intellect Neurosciences Issues Letter to Shareholders 12:33 p.m. Feb. 13, 2013 - GlobeNewswire
Intellect Neurosciences Initiates in vivo Proof of Concept Studies in a Preclinical Alzheimer's Model for Its TauC3 Monoclonal Antibody 9:35 a.m. Feb. 7, 2013 - GlobeNewswire
Novel Alzheimer's Therapeutics Developer Says Investors Should Remain Undeterred Despite Disappointing Results From Major Phase 3 Trials 8:08 a.m. Jan. 30, 2013 - Marketwire
(0)
(0)Scroll down for more posts ▼